EyeCool Therapeutics Announces New ETX-4143 Data to Be Presented at ARVO 2026By: EyeCool Therapeutics, Inc. The abstracts add to growing evidence supporting the safety and therapeutic potential of ETX-4143 to treat chronic ocular surface pain (COSP), a debilitating condition with no FDA-approved treatments. In a one-year follow-up of 19 treated subjects: Treated eyes maintained improved best-corrected visual acuity, and mean pain scores for 60% of subjects remained below baseline. Corneal nerve sensitivity improved toward normal healthy adult levels at Week 8 and was maintained at one year. Safety evaluations found no adverse ocular effects, no anterior segment inflammation, no limbal cell or angle structure damage, and normal findings in treated and untreated fellow eyes. A second study using in vivo confocal microscopy (IVCM) confirmed that corneal nerve metrics and ocular surface parameters were maintained after treatment. Eye pain was significantly reduced on the Visual Analog Scale (mean change −52 units, p = 0.04) and a validated patient-reported outcome instrument. Functional IVCM (Fun-IVCM) analyses showed that ETX-4143 reduced epithelial T cell motility and dendritic cell probing activity by 12 weeks post-treatment, suggestive of an immunomodulatory effect. "In addition to providing assurance around the maintenance of corneal nerve anatomical integrity, these novel in vivo data identify the modulation of human corneal immune cell activity at 12 weeks follow-up, after a single in-office treatment. They provide exciting initial evidence for a clinical link between a reduction in ocular surface pain and sustained alterations to corneal immune cell behaviors," said Professor Laura E. Downie, PhD, of the University of Melbourne, a chief investigator on the feasibility study. Additional findings from a recently completed clinical trial in Australia are expected to be submitted for publication in a peer-reviewed journal and presented at future meetings. About EyeCool Therapeutics Inc. EyeCool Therapeutics is a clinical stage medical device company committed to innovation and novel therapies for eye care. EyeCool is focused on developing an in-clinic device to deliver fast, lasting relief for patients suffering from Chronic Ocular Surface Pain. About Chronic Ocular Surface Pain Chronic ocular surface pain (COSP) is a common ocular condition defined as having a feeling of pain or discomfort, perceived as originating from the ocular surface, that persists for more than three months. There are currently no approved treatment options for COSP. Important Safety Information Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device. For more information, please visit www.eyecooltx.com. End
|
|
Account Phone Number